The increase in the price target by a reputable analyst such as Yanan Zhu from Wells Fargo is a strong positive signal for Iovance Biotherapeutics. It suggests confidence in the company's future performance and potential for growth, which is likely to be viewed favorably by investors. This endorsement could lead to increased investor interest and potentially a rise in the stock price in the short term.